Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research7/28/2026Positive
JAZZ
Jazz Pharmaceuticals PLCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$16.14B
P/E Ratio
2569.20
EPS
$0.10
Beta
0.32
52W High
$261.30
52W Low
$105.00
50-Day MA
$238.04
200-Day MA
$189.57
Dividend Yield
—
Profit Margin
0.66%
Forward P/E
10.92
PEG Ratio
0.96
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.
Fundamentals
| Revenue (TTM) | $4.44B |
| Gross Profit (TTM) | $4.06B |
| EBITDA | $2.01B |
| Operating Margin | 23.50% |
| Return on Equity | 0.68% |
| Return on Assets | 6.92% |
| Revenue/Share (TTM) | $72.52 |
| Book Value | $72.28 |
| Price-to-Book | 3.54 |
| Price-to-Sales (TTM) | 3.64 |
| EV/Revenue | 4.188 |
| EV/EBITDA | 27.53 |
| Quarterly Earnings Growth (YoY) | 3.20% |
| Quarterly Revenue Growth (YoY) | 19.10% |
| Shares Outstanding | $62.82M |
| Float | $60.80M |
| % Insiders | 3.08% |
| % Institutions | 107.78% |
Historical Volatility
HV 10-Day
28.16%
HV 20-Day
26.67%
HV 30-Day
25.79%
HV 60-Day
30.29%
HV Rank
21.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($266.90 target)
7
Strong Buy10
Buy1
Hold1
Strong SellLatest News
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research7/27/2026Positive
Is JAZZ Still the Best Cannabis Stock After Federal Rescheduling?
Jazz Pharmaceuticals pairs its FDA-approved CBD blockbuster with a diversified drug portfolio, offering medical cannabis exposure despite ongoing pipeline risks.
Zacks Investment Research7/24/2026Positive
These major drug stocks rally after Trump's zero tariff announcement
President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.
Finbold7/22/2026Positive
Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks Investment Research7/21/2026Positive
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026
DUBLIN, July 20, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m.
PRNewsWire7/20/2026Neutral
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research7/6/2026Positive
Jazz Pharmaceuticals (JAZZ) Price Forecast: Will Breakout Confirm Higher Highs?
Jazz Pharmaceuticals is testing a bull flag breakout following a long-term base advance, with confirmation needed above key swing resistance to validate continuation toward new highs.
FXEmpire7/2/2026Positive
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research6/30/2026Positive
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies
Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.
Zacks Investment Research6/18/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on JAZZ and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026